Application of inhibitors targeting ISL1 in the preparation of anti-tumor drugs

By developing a small molecule inhibitor 10044068 targeting ISL1, the problem of limited efficacy of existing anti-hepatitis cancer drugs has been solved, effective inhibition of hepatocellular carcinoma and gastric cancer has been achieved, and new therapeutic strategies have been provided.

CN118542870BActive Publication Date: 2024-11-19BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411018216.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-19
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

The existing anti-hepatocellular carcinoma drugs have limited efficacy on primary hepatocellular carcinoma and are highly resistant. The lack of effective ISL1 inhibitors makes it difficult to effectively inhibit tumor growth.

Method used

A small molecule inhibitor targeting ISL1 was developed. Small molecule compound 10044068 was screened from the Chembridge drug target library through a virtual drug screening platform. It combines the ISL1 protein structure to verify its binding ability and anti-tumor effect with ISL1. In preparation of anti-hepatic and gastric cancer treatment drugs.

Benefits of technology

Small molecule compound 10044068 significantly inhibited the growth of liver and gastric cancer cells. By verifying its effectiveness in Hep-12 cells and mouse models, it provides a new ISL1 inhibitor for hepatocellular carcinoma treatment with significant tumor suppression effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118542870B_ABST
    Figure CN118542870B_ABST
Patent Text Reader

Abstract

The present invention provides an application of an inhibitor targeting ISL1 in the preparation of an anti-tumor drug, and belongs to the field of medical technology. Based on the protein structure of ISL1, the present invention uses virtual drug screening technology to screen out small molecules with top scores from the Chembridge drug target library, and further uses a cell sphering ability experiment for screening to screen out active compounds that potentially inhibit cell sphering ability, including compounds of formula I. The binding ability of small molecules to ISL1 is detected by surface plasmon resonance and the IC50 of small molecules is detected by CCK‑8 experiment, and the in vivo tumor inhibition effect of small molecules is verified by animal tumor formation experiment. The small molecule inhibitor of ISL1 can significantly inhibit the sphering ability of cells in serum-free culture medium, and inhibit the growth of Hep‑12 cell mouse transplant tumors, has a significant anti-tumor effect, and is expected to be used as a lead compound for the treatment of ISL1 high-expressing tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to application of an inhibitor targeting ISL1 in the preparation of anti-tumor drugs. Background Art

[0002] Hepatocellular carcinoma (HCC) is the main histological subtype of liver cancer, accounting for 90% of primary liver cancer, and is one of the cancers with high morbidity and mortality worldwide. HCC is extremely malignant and has a very poor prognosis. Orthotopic liver transplantation and surgical resection are the best treatments for patients with early liver cancer, but the five-year survival rate of patients is extremely low due to the recurrence and metastasis of liver cancer after surgery. Most patients are already in the middle and late stages when diagnosed, and have lost the opportunity for radical treatment. Chemotherapy is often used to prolong life. Compared with surgery, chemotherapy using anti-liver cancer drugs has the advantages of alleviating patient pain, reducing treatment risks, and improving patient quality of life. Although the molecular targeted drugs sorafenib and lenvatinib on the market are first-line drugs for anti-liver cancer, they can only prolong the median survival of patients by about one year, and are not sensitive to primary liver cancer. They are often unable to continue to be used due to drug resistance and poor basic conditions, thus failing to achieve the expected therapeutic effect. Therefore, it is crucial to find new anti-tumor drugs.

[0003] Insulin enhancer binding protein-1 (ISL1) is a LIM homeodomain transcription factor that plays an important role in gene transcriptional regulation. ISL1 regulates the differentiation and development of cardiovascular, pancreatic, and nervous system tissues and organs during embryonic development. After birth, the expression of ISL1 is highly tissue-specific and is only expressed in pancreatic islets and some neural tissues. The expression of ISL1 in other tissues may indicate the occurrence of tumors. Our work and that of others have shown that the expression level of ISL1 in tumor tissues is significantly higher than that in adjacent tissues, and that high expression in tumor tissues is closely related to patient survival. Knocking out the expression of ISL1 can significantly inhibit tumor growth and may serve as a therapeutic target. However, there are currently no ideal ISL1 inhibitors on the market. Therefore, the development of an effective ISL1 small molecule inhibitor has become an urgent problem to be solved, which is expected to provide a new strategy for the treatment of tumors. Summary of the invention

[0004] In order to solve the above technical problems, the object of the present invention is to provide an application of an inhibitor targeting ISL1 in the preparation of an anti-tumor drug.

[0005] In a first aspect of the present invention, a small molecule inhibitor targeting ISL1 is provided, wherein the structural formula of the small molecule inhibitor is as shown in Formula I:

[0006]

[0007] Formula I.

[0008] In a second aspect of the present invention, a small molecule inhibitor of ISL1 is provided, which has the ability to bind to arginine at positions 183 and 185 of ISL1.

[0009] The third aspect of the present invention provides the use of the small molecule inhibitor targeting ISL1 in the preparation of therapeutic drugs for tumors with high ISL1 expression, such as liver cancer and gastric cancer.

[0010] A fourth aspect of the present invention provides a drug for treating hepatocellular carcinoma, wherein the active ingredient of the drug is the ISL1 small molecule inhibitor.

[0011] Furthermore, the medicine also includes pharmaceutical excipients.

[0012] Furthermore, the drug preparation forms include injections, tablets, capsules, aerosols, suppositories, films, controlled-release or sustained-release preparations or nano preparations.

[0013] Beneficial effects of the present invention:

[0014] Based on the structure of ISL1 protein, the present invention uses a virtual drug screening platform to screen small molecules with top scores from the Chembridge drug target library for real screening, screen active small molecules that inhibit the sphering ability of Hep-12 cells, and screen out 4 potential active compounds including 10044068 (compound of formula I) from the active small molecules. The binding ability of small molecules to proteins is verified by SPR, and cell proliferation is detected by CCK-8 experiment; in addition, it is verified on Hep-12 transplanted tumor mice that mice given active small molecules can effectively inhibit tumor growth, thereby achieving an anti-tumor effect.

[0015] The present invention combines computational simulation screening and ISL1 protein and small molecule inhibitor binding test experiments to quickly and effectively screen out effective ISL1 small molecule inhibitors. The screened inhibitors have definite effects in the evaluation of mouse tumor-bearing models and have application prospects for the treatment of hepatocellular carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0018] Figure 1 This is a statistical result diagram of the number of spheres formed by Hep-12 cells treated with four small molecule compounds in the present invention;

[0019] Figure 2 This is an optical photograph of the sphering effect of Hep-12 cells treated with four small molecule compounds in the present invention;

[0020] Figure 3 This is a result diagram of the effects of the four small molecule compounds of the present invention on the protein expression level of CACNA2D1;

[0021] Figure 4 This is a graph showing the effect of the small molecule inhibitor of the present invention on the inhibition of Hep-11 and Hep-12 cell proliferation;

[0022] Figure 5 This is the electrophoresis result of the purified ISL1 protein in the present invention;

[0023] Figure 6 This is a graph showing the affinity test results between the ISL1 protein and the small molecule compound 10044068 in the present invention;

[0024] Figure 7 It is a docking structure binding mode diagram of the small molecule inhibitor of the present invention and the ISL1 protein;

[0025] Figure 8 The results of affinity test of small molecule inhibitors of the present invention with GST protein and truncated fusion protein are shown;

[0026] Fig. 9 This is a graph showing the affinity test results of the small molecule inhibitor and the ISL1 mutant protein of the present invention;

[0027] Fig.10 The effect of the small molecule inhibitor of the present invention on the tumor after the human liver cancer cell Hep-12 is loaded;

[0028] Fig.11 This is a graph showing the change in tumor volume before and after treatment with the small molecule inhibitor of the present invention;

[0029] Fig.12 This is a graph showing the changes in body weight of nude mice before and after treatment with the small molecule inhibitor of the present invention;

[0030] Fig.13This is a graph showing the tumor weight results before and after treatment with the small molecule inhibitor of the present invention;

[0031] Fig.14 This is a morphological observation result diagram of the inhibition of gastric cancer organoid proliferation by the small molecule inhibitors of the present invention;

[0032] Fig.15 This is a graph showing the results of the small molecule inhibitors of the present invention inhibiting the proliferation of gastric cancer organoids. DETAILED DESCRIPTION

[0033] In order to more clearly understand the above-mentioned objectives, features and advantages of the present invention, the scheme of the present invention will be further described below. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

[0034] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein; it is obvious that the embodiments in the specification are only part of the embodiments of the present invention, rather than all of the embodiments.

[0035] The experimental methods without specific conditions and reagents without formulas in the following examples are all based on conventional conditions.

[0036] Experimental Materials:

[0037] 1. Cell lines: Hep-11 and Hep-12 liver cancer cell lines were provided by the laboratory of Beijing Institute of Cancer Prevention and Treatment.

[0038] 2. Organoids: Gastric cancer organoids were provided by the laboratory of Beijing Institute of Cancer Prevention and Treatment.

[0039] 3. Experimental animals: Female nude mice, 4-6 weeks old, were purchased from Beijing Huafukang Biotechnology Co., Ltd. and raised by the Animal Center of Beijing Cancer Research Institute. All animal experimental procedures were approved by the Laboratory Animal Care and Use Association of Beijing Cancer Research Institute.

[0040] 4. Main experimental reagents: Small molecule compounds 10044068, 35595356, 66356301 and 19220565 (public website: https: / / chembridge.com / search / ) were purchased from WuXi AppTec, RPMI-1640 medium was purchased from Gibico, restriction endonucleases were purchased from NEB, T4-DNA ligase was purchased from Promaga, trypsin was purchased from Gibico, E.Coli. competent strain DH5α was purchased from Quanshijin, CACNA2D1 antibody was purchased from Sigma, CCK-8 kit was purchased from Dojindo, and matrix gel was purchased from Corning.

[0041]

[0042] Example 1

[0043] In this example, small molecule inhibitors targeting ISL1 were preliminarily screened through computer virtual screening.

[0044] The crystal complex structure of ISL1 inhibitor based on ISL1 was downloaded from the PDB database (PDB ID: 4jcj); its full-length structure was used for docking with small molecules; the Glide docking algorithm in the Schrödinger software package was used for virtual screening of the Chembridge commercial compound database; after screening, the top 1000 compound molecules were screened based on Lipinski drug-like rules, cluster analysis, etc., and the top 100 diverse molecules were obtained for subsequent experimental testing (Table 1).

[0045] Table 1 Numbers and names of the top 100 small molecule compounds from computer virtual screening based on the ISL1 structure

[0046]

[0047] Example 2

[0048] This example verifies the effect of the top small molecule compounds on the spheroid formation of Hep-12 cells through a spheroid formation experiment.

[0049] (1) Take Hep-12 cells growing in the logarithmic phase, wash them with CMF solution, digest them with trypsin, resuspend the cells in RPMI-1640 complete medium with 10% serum, centrifuge the cell suspension at 1000 rpm for 5 min, resuspend the cell pellet in serum-free RPMI-1640 medium, and filter through a 400-mesh cell sieve to prepare a single-cell suspension;

[0050] (2) Count the cells using a cell counter and take 900 cells and add them to 900 µL of spheroid formation medium (DMEM / F12 medium, containing 1% methylcellulose, B27 additive, 10 ng / mL hepatocyte growth factor, 20 ng / mL epidermal growth factor, 20 ng / mL fibroblast growth factor). Add the compound to the medium as the experimental group and DMSO as the blank control group. Use a pipette to fully resuspend and inoculate 100 µL (100 cells) per well in a low-adhesion 96-well plate. Set three concentrations of 10 nM, 100 nM, and 1000 nM for each compound, with 6 replicate wells in each group. Add 100 µL of fresh spheroid formation medium to each well for about one week to observe the spheroid formation. When the diameter of the spheroids in the blank control group reaches 100 µm, take pictures under a microscope and count the number of spheroids with a diameter ≥100 µm formed per 100 cells.

[0051] The results are as follows Figure 1 and Figure 2 As shown, Figure 1 This is the statistical result of the number of spheres formed by Hep-12 cells treated with four small molecule compounds. Figure 2 The optical photos of Hep-12 cells spheroidized after being treated with four small molecule compounds. Figure 1 and 2 It can be seen that the four small molecule compounds 35595356, 10044068, 66356301 and 19220565 can significantly inhibit the sphere formation of Hep-12 cells at a low concentration dose (10nM), indicating that these four small molecule compounds can significantly affect the self-renewal ability of hepatocellular carcinoma tumor cells.

[0052] Example 3

[0053] In this example, protein immunoblotting experiments were performed to verify the effects of the aforementioned four small molecule compounds on the protein expression level of CACNA2D1, a downstream target gene directly regulated by ISL1.

[0054] The specific steps are as follows:

[0055] The above four small molecule compounds were added to RPMI-1640 medium containing 10% serum at final concentrations of 0 nM, 10 nM, 100 nM, and 1000 nM, respectively, and Hep-12 cells were cultured for 24 h, the medium containing small molecule compounds was discarded, the cells were washed 3 times with pre-cooled PBS buffer, the total cell protein was extracted, and the above proteins were subjected to electrophoresis and membrane transfer. Further, CACNA2D1 antibody and corresponding secondary antibody were used for antibody incubation, and chemiluminescent solution was prepared for color development.

[0056] The results are as follows Figure 3As shown, Figure 3 The figure shows the effect of four small molecule compounds on the protein expression level of CACNA2D1. Figure 3 It can be seen that the small molecule compound 10044068 inhibited the protein expression of CACNA2D1 in a dose-dependent manner, while the other three small molecule compounds had no obvious effect on its protein expression, indicating that the small molecule compound 10044068 can inhibit the protein expression of the ISL1 target gene.

[0057] Example 4

[0058] In this example, the CCK8 method was used to detect the effect of the small molecule compound 10044068 on the proliferation of ISL1-negative Hep-11 cells and ISL1-highly expressed Hep-12 cells.

[0059] The specific steps are as follows:

[0060] (1) Cell plating: When the cells grow to 80% of the culture dish, digest them with trypsin for 5 min, add RPMI-1640 complete medium containing 10% serum to terminate digestion, and centrifuge at 1000 rpm for 5 min. Discard the supernatant, resuspend the cells in complete medium, count, and adjust the cell density to 3×10 5 Cells were seeded in 96-well plates, 100 uL of cell suspension was added to each well, and the plates were cultured in a 37°C incubator.

[0061] (2) Cell administration: Different concentrations of the small molecule compound 10044068 (0 μM, 2 μM, 4 μM, 8 μM, 16 μM, 32 μM, 64 μM, 128 μM, 256 μM, 512 μM) were added to the wells containing cells.

[0062] (3) CCK-8 experiment: 24 h after drug addition, the culture medium was discarded and CCK-8 solution (prepared to contain 10% CCK-8) was added. The 96-well plate was placed in an incubator and incubated for 2 h. The absorbance at 450 nm was measured with a microplate reader to calculate the relative cell viability.

[0063] Relative cell viability = [(As-Ab) / (Ac-Ab)] × 100%;

[0064] As: absorbance of the experimental group (including cells, culture medium, CCK-8 and drug solution);

[0065] Ac: absorbance of the control group (containing cells, culture medium, CCK-8, but no drugs);

[0066] Ab: absorbance of blank group (containing culture medium and CCK-8, but without cells and drugs).

[0067] The results are as follows Figure 4 As shown, Figure 4 This is the result of CCK-8 testing of the effect of different concentrations of small molecule compound 10044068 on the proliferation of ISL1-negative Hep-11 and ISL1-positive Hep-12 cells. Figure 4 It can be seen that the IC50 of Hep-11 cells to 10044068 is 1308 μM, and the IC50 of Hep-12 cells is 143.4 μM. Hep-12 cells with high expression of ISL1 show higher sensitivity to the small molecule compound 10044068, indicating that the small molecule compound 10044068 is a potential effective inhibitor that is highly sensitive to ISL1.

[0068] Example 5

[0069] In this example, affinity detection was performed by surface plasmon resonance (SPR) to verify the affinity between the small molecule compound 10044068 and ISL1.

[0070] The specific steps are as follows:

[0071] 1. PGEX-ISL1 Plasmid Construction

[0072] (1) The mRNA sequence of the ISL1 gene was searched on NCBI (Accession: NM_002202.3), and its CDS region was retrieved. Primer sequences were designed upstream and downstream of the CDS sequence, and BamHI and XhoI restriction site sequences and protective bases were introduced. The primer sequences were sent to Sangon Biotech Co., Ltd. for synthesis;

[0073] The primer sequences are as follows:

[0074] Upstream primer (F): 5′-CGGGATCCATGGGAGACATGGGAGATCCACC-3′ (SEQ ID NO: 1);

[0075] Downstream primer (R): 5′-CCGCTCGAGTGCCTCAATAGGACTGGCTAC-3′ (SEQ ID NO: 2);

[0076] (2) The full-length sequence of ISL1 was obtained by PCR amplification using Hep-12 cell cDNA as a template;

[0077] (3) The restriction endonucleases BamHI and XhoI were used to digest the PGEX vector and the ISL1 target fragment, and the purified linearized vector and target fragment were recovered by agarose gel;

[0078] (4) Connect the linearized vector and the target fragment using the T4 ligation method;

[0079] (5) Use competent DH5α to transform the ligation product, plate the bacterial solution, culture for 12-16 hours, select single clone colonies to extract plasmids, perform restriction enzyme digestion and verification, and identify the correct positive clones for sequencing;

[0080] (6) Plasmid extraction was performed on the cloned samples that were sequenced correctly to obtain the PGEX-ISL1 plasmid.

[0081] 2. ISL1 protein expression and purification

[0082] (1) Use BL21 competent cells to transform the PGEX-ISL1 plasmid;

[0083] (2) Pick a strain expressing a single clone and inoculate it into 4 mL of LB medium containing ampicillin (100 μg / mL), and culture it at 37°C overnight;

[0084] (3) Take the bacterial culture overnight and inoculate it into 200 mL of LB medium containing ampicillin (100 μg / mL) at a volume ratio of 1:100.

[0085] (4) Cultivate for about 2 h until the OD600 of the bacterial solution reaches about 0.6, add IPTG (isopropylthiogalactoside) to a final concentration of 0.4 mM, and culture at 16°C for 16 h;

[0086] (5) Collect the bacterial solution into a centrifuge tube, centrifuge at 4°C, 4000g for 20 min, discard the supernatant, and collect the precipitate;

[0087] (6) Add 10 mL of lysis buffer containing protease inhibitors and lysozyme to 1 mg / mL and place in an ice water bath or on ice for 30 min.

[0088] (7) Ultrasonic lysis of bacteria on ice, with an ultrasonic power of 200-300 W, six times, each ultrasonic treatment for 10 s, and then standing on ice for 10 s until the bacterial solution is clear;

[0089] (8) Centrifuge at 10,000 g for 20 min at 4°C, collect the supernatant and place in an ice-water bath or on ice;

[0090] (9) Take 1 mL of the mixed GST-bound beads, centrifuge at 3000 rpm at 4°C to discard the storage solution, resuspend the beads with the wash solution, centrifuge and discard the liquid;

[0091] (10) Add the bacterial supernatant to the beads and incubate at 4°C for 6 h.

[0092] (11) The liquid was removed by centrifugation, and the beads were washed three times with PBS buffer. The GST tag was directly cut off on the beads using thrombin to obtain purified ISL1 protein. The purified ISL1 protein was then detected by electrophoresis.

[0093] 4. Surface Plasmon Resonance (SPR) Affinity Detection

[0094] The ISL1 protein with a final concentration of 200 μg / mL was coupled to the CM5 chip using an amino coupling kit. According to the protein coupling calculation formula provided by GE, the protein coupling process was performed on a Biacore 8K surface plasmon resonance instrument, and the final protein coupling amount was 20,000 RU. The in vitro binding capacity of compound 10044068 and ISL1 protein was tested. The compound was dissolved in DMSO to 10 mM as a stock solution, and diluted with running buffer to a final concentration of 1.5625 μM, 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM, and 200 μM, 200 μL each, and the KD value was calculated by affinity fitting using the software.

[0095] The results are as follows Figure 5 and Figure 6 As shown, Figure 5 This is the electrophoresis diagram of purified ISL1 protein. Figure 6 The results of the affinity test between ISL1 protein and small molecule compound 10044068 at different concentrations are shown in Figure 2. Figure 5 It can be seen that the electrophoresis band of the purified ISL1 protein is single and narrow, indicating that pure ISL1 protein is obtained. Figure 6 It can be seen that ISL1 has a micromolar affinity with the small molecule compound 10044068, KD=2.18 μM, indicating that ISL1 has a strong binding ability with the small molecule compound 10044068.

[0096] Example 6

[0097] In this example, molecular docking and SPR experiments were used to further detect the key domains and binding sites of small molecule inhibitors binding to ISL1 protein.

[0098] The specific steps are as follows:

[0099] First, based on the structure of ISL1 protein and small molecule inhibitors, we used molecular docking technology to predict the key domains and binding sites of small molecule inhibitors on ISL1 protein. Based on the predicted results, we constructed a truncated plasmid of the domain and expressed the truncated fusion protein, and used SPR experiments to detect the affinity of the small molecule inhibitor and the truncated protein. Furthermore, we mutated the predicted key binding sites, constructed ISL1 site mutation plasmids and expressed the corresponding site mutation proteins, and used SPR experiments to detect the affinity of the small molecule inhibitor and ISL1 site mutation proteins.

[0100] The results are as follows Figure 7-9 As shown, Figure 7 It is a docking structure binding pattern diagram of the small molecule inhibitor of the present invention and the ISL1 protein. Figure 8 This is a graph showing the affinity test results of small molecule inhibitors with GST protein and truncated fusion protein. Fig. 9 The following is the result of affinity test between small molecule inhibitors and ISL1 mutant proteins. Figure 7 It can be seen that the small molecule inhibitor mainly binds to the homologous domain of the ISL1 protein (180-251 amino acid region), and it may mainly bind to nine amino acid sites: R183, R185, T186, L188, L193, V224, V227, W228 and N231. Figure 8 It can be seen that the small molecule inhibitor has no binding to the GST protein, but has a strong binding ability to the truncated fusion protein, and its binding constant is 1.09 μM, which is close to the binding constant of the full-length ISL1 protein, indicating that the small molecule inhibitor binds to the homologous domain of the ISL1 protein. Fig. 9 It can be seen that after the mutation of the two amino acid sites R183 and R185, the binding ability of small molecule inhibitors to ISL1 protein was significantly weakened, while after the mutation of the seven amino acid sites T186, L188, L193, V224, V227, W228 and N231, the binding of small molecule inhibitors to ISL1 protein was not significantly affected, indicating that the small molecule inhibitors mainly bind to the two amino acid sites R183 and R185.

[0101] Example 7

[0102] This example verifies the therapeutic effect of the small molecule compound 10044068 on HCC xenograft tumors through a tumor-bearing mouse administration experiment.

[0103] The specific steps are as follows:

[0104] (1) Model establishment: Hep-12 cells in the logarithmic growth phase were obtained, digested, resuspended, washed twice with PBS, and resuspended in an appropriate amount of serum-free RPMI-1640 medium; after counting with a cell counter, the cell density was adjusted to 2×107 / mL, use a 1 mL sterile syringe to draw up the cell suspension and inoculate it subcutaneously on the back of the right hind limb of nude mice, and inoculate 100 µL of cell suspension per mouse;

[0105] (2) Animal grouping: When the tumor grows to about 100 mm 3 At the same time, mice with tumors that were too large or too small were removed, and the remaining mice were evenly divided into three groups, a low-dose group of small molecule compound 10044068 (2 mg / kg), a high-dose group of small molecule compound (10 mg / kg), and a control group, with 8 mice in each group;

[0106] (3) Administration and observation: The small molecule compound 10044068 was administered orally daily at a low dose of 2 mg / kg and a high dose of 10 mg / kg (the small molecule compound 10044068 was dissolved in a solvent consisting of 40% PEG300, 5% Tween 80 and 55% saline, and the control group was the solvent). The body weight and tumor volume of the mice were recorded on the day of administration, and the status of the mice was observed. The body weight and tumor volume of the mice were weighed every other day. When the maximum tumor volume of the mice in the control group reached 1.5 cm 3 The experiment was terminated at about 1:10 pm, and the mice were killed by cervical dislocation. The tumors were dissected and photographed and weighed. Finally, the tumors were divided into two parts, fixed with paraformaldehyde and stored at room temperature, and quickly frozen with liquid nitrogen and stored at -80°C.

[0107] (4) Experimental data collation: After the experiment, the weight change curve, tumor volume growth curve and tumor weight distribution diagram of each group of mice were drawn. Tumor inhibition rate was calculated:

[0108] The formula for calculating tumor inhibition rate is IR (%) = (1-TTW / CTW) × 100%

[0109] TTW: tumor weight of the treatment group; CTW: tumor weight of the control group.

[0110] The results are as follows Figure 10-13 shown. Fig.10 These are photos of tumors in tumor-bearing mice that received different dosages of medication. Fig.11 The curve diagram of tumor volume changes in tumor-bearing mice treated with different dosages is shown in Figure 2. Fig.12 The curve diagram of body weight change of tumor-bearing mice treated with different dosages. Fig.13 The figure is a statistical analysis result of the tumor weight of tumor-bearing mice at different dosages (two-sided T test statistical analysis). Figure 10-13 It can be seen that the small molecule compound 10044068 can effectively inhibit the growth of Hep-12 transplanted tumor mice at both high and low doses. The tumor inhibition rate of the low-dose group was 72%, and the tumor inhibition rate of the high-dose group reached 81%. Fig.12It can be seen that there is no significant difference in body weight among the groups of mice, indicating that the small molecule compound 10044068 has no obvious toxic side effects on mice.

[0111] Example 8

[0112] In this example, the CCK8 method was used to detect the effect of the small molecule compound 10044068 on the growth activity of gastric cancer organoids.

[0113] The specific steps are as follows:

[0114] (1) Take out the gastric cancer organoid sample to be tested, carefully remove the original culture medium along the edge, add digestion solution to the culture plate, gently blow the matrix gel, and place it in a 37°C incubator for 15 min. Add the stop buffer to stop the digestion, resuspend and mix thoroughly, take 20 μL of the suspension and spot it on the counting plate, count and record. Take 3000 cells from each well and resuspend them in 100 μL of culture medium containing 5% matrix gel, mix well, add to the 96-well plate, and place it in the incubator.

[0115] (2) Use culture medium to dilute the small molecule drug 10044068, set 9 concentration gradients, namely 500 μM, 100 μM, 50 μM, 10 μM, 5 μM, 1 μM, 100 nM, 10 nM and 0 nM, and set 3 replicates for each concentration. Take out the organoid samples to be tested, carefully discard the original culture medium, add the above drug-containing culture medium respectively, and culture them in the incubator.

[0116] (3) 96 hours after drug addition, the survival rate of the organoids was detected according to the method in step (3) of Example 4.

[0117] The results are as follows Fig.14 and Fig.15 As shown, Fig.14 This is a morphological observation result of the inhibition of gastric cancer organoid proliferation by the small molecule compound 10044068. Fig.15 The results of the inhibition of gastric cancer organoid proliferation by small molecule compound 10044068 at different concentrations are shown in Figure 2. Fig.14 and Fig.15 It can be seen that the small molecule compound 10044068 inhibits the growth of gastric cancer organoids in a dose-dependent manner. As the drug concentration increases, the proliferation rate of the organoids decreases and the size decreases. At high concentrations, the organoids undergo apoptosis and fragmentation. This shows that the small molecule compound can kill gastric cancer organoids and provide potential guidance for the clinical treatment of gastric cancer.

[0118] In summary, there is a strong affinity between the small molecule compound 10044068 and ISL1 at the micromolar level. As an ISL1 inhibitor, the small molecule compound 10044068 can not only significantly inhibit the proliferation of HCC cells and the ability to form spheroids in vitro, but also inhibit the growth of gastric cancer organoids, and has a good inhibitory effect on tumor growth in animal models. Therefore, the ISL1 inhibitor 10044068 can be used to develop drugs for tumors with high ISL1 expression, and the anti-tumor drug has good therapeutic application prospects for tumor types with high ISL1 expression.

[0119] It should be noted that, in this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, the elements defined by the sentence "comprise a ..." do not exclude the existence of other identical elements in the process, method, article or device including the elements.

[0120] The above description is only a specific embodiment of the present invention, so that those skilled in the art can understand or implement the present invention. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments described herein, but should conform to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Application of inhibitors targeting ISL1 in the preparation of anti-tumor drugs, It is characterized in that The inhibitor targeting ISL1 has a structure shown in Formula I; Formula I.

2. The use according to claim 1, It is characterized in that The inhibitor targeting ISL1 has the ability to bind to arginine at positions 183 and 185 of ISL1.

3. An anti-tumor drug, It is characterized in that The anti-tumor drug includes an inhibitor targeting ISL1, and the inhibitor targeting ISL1 has a structure shown in Formula I; Formula I.

4. The antitumor drug according to claim 3, It is characterized in that The anti-tumor drug also includes pharmaceutically acceptable auxiliary materials or carriers.

5. The antitumor drug according to claim 3, It is characterized in that The tumor is a tumor that highly expresses ISL1.

6. The antitumor drug according to claim 5, It is characterized in that The tumor is liver cancer or gastric cancer.